372 related articles for article (PubMed ID: 21712032)
61. New drugs for ALS: how do we get there?
Glass JD
Exp Neurol; 2012 Jan; 233(1):112-7. PubMed ID: 22033032
[No Abstract] [Full Text] [Related]
62. Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS.
Kalmar B; Novoselov S; Gray A; Cheetham ME; Margulis B; Greensmith L
J Neurochem; 2008 Oct; 107(2):339-50. PubMed ID: 18673445
[TBL] [Abstract][Full Text] [Related]
63. Overview of Impaired BDNF Signaling, Their Coupled Downstream Serine-Threonine Kinases and SNARE/SM Complex in the Neuromuscular Junction of the Amyotrophic Lateral Sclerosis Model SOD1-G93A Mice.
Just-Borràs L; Hurtado E; Cilleros-Mañé V; Biondi O; Charbonnier F; Tomàs M; Garcia N; Lanuza MA; Tomàs J
Mol Neurobiol; 2019 Oct; 56(10):6856-6872. PubMed ID: 30929165
[TBL] [Abstract][Full Text] [Related]
64. Immune response in peripheral axons delays disease progression in SOD1
Nardo G; Trolese MC; de Vito G; Cecchi R; Riva N; Dina G; Heath PR; Quattrini A; Shaw PJ; Piazza V; Bendotti C
J Neuroinflammation; 2016 Oct; 13(1):261. PubMed ID: 27717377
[TBL] [Abstract][Full Text] [Related]
65. Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis.
Neymotin A; Petri S; Calingasan NY; Wille E; Schafer P; Stewart C; Hensley K; Beal MF; Kiaei M
Exp Neurol; 2009 Nov; 220(1):191-7. PubMed ID: 19733563
[TBL] [Abstract][Full Text] [Related]
66. The Smn-independent beneficial effects of trichostatin A on an intermediate mouse model of spinal muscular atrophy.
Liu H; Yazdani A; Murray LM; Beauvais A; Kothary R
PLoS One; 2014; 9(7):e101225. PubMed ID: 24984019
[TBL] [Abstract][Full Text] [Related]
67. Effects of Tongue Force Training on Bulbar Motor Function in the Female SOD1-G93A Rat Model of Amyotrophic Lateral Sclerosis.
Ma D; Shuler JM; Kumar A; Stanford QR; Tungtur S; Nishimune H; Stanford JA
Neurorehabil Neural Repair; 2017 Feb; 31(2):147-156. PubMed ID: 27573800
[TBL] [Abstract][Full Text] [Related]
68. Moderate modulation of disease in the G93A model of ALS by the compound 2-(2-hydroxyphenyl)-benzoxazole (HBX).
Evans TM; Bhattacharya A; Shi Y; Qi W; Block TJ; Chaudhuri A; Chaudhuri AR; Hawker K; Van Remmen H
Neurosci Lett; 2016 Jun; 624():1-7. PubMed ID: 27138280
[TBL] [Abstract][Full Text] [Related]
69. Adipose-derived stem cell conditioned medium impacts asymptomatic peripheral neuromuscular denervation in the mutant superoxide dismutase (G93A) transgenic mouse model of amyotrophic lateral sclerosis.
Walker CL; Meadows RM; Merfeld-Clauss S; Du Y; March KL; Jones KJ
Restor Neurol Neurosci; 2018; 36(5):621-627. PubMed ID: 30010155
[TBL] [Abstract][Full Text] [Related]
70. Upregulation of Vesicular Glutamate Transporter 2 and STAT3 Activation in the Spinal Cord of Mice Receiving 3,3'-Iminodipropionitrile.
Ohgomori T; Yamasaki R; Kira JI; Jinno S
Neurotox Res; 2018 May; 33(4):768-780. PubMed ID: 28965218
[TBL] [Abstract][Full Text] [Related]
71. Histone deacetylase 4 protects from denervation and skeletal muscle atrophy in a murine model of amyotrophic lateral sclerosis.
Pigna E; Simonazzi E; Sanna K; Bernadzki KM; Proszynski T; Heil C; Palacios D; Adamo S; Moresi V
EBioMedicine; 2019 Feb; 40():717-732. PubMed ID: 30713114
[TBL] [Abstract][Full Text] [Related]
72. Targeting Extracellular Cyclophilin A Reduces Neuroinflammation and Extends Survival in a Mouse Model of Amyotrophic Lateral Sclerosis.
Pasetto L; Pozzi S; Castelnovo M; Basso M; Estevez AG; Fumagalli S; De Simoni MG; Castellaneta V; Bigini P; Restelli E; Chiesa R; Trojsi F; Monsurrò MR; Callea L; Malešević M; Fischer G; Freschi M; Tortarolo M; Bendotti C; Bonetto V
J Neurosci; 2017 Feb; 37(6):1413-1427. PubMed ID: 28011744
[TBL] [Abstract][Full Text] [Related]
73. Minocycline delays disease onset and mortality in a transgenic model of ALS.
Van Den Bosch L; Tilkin P; Lemmens G; Robberecht W
Neuroreport; 2002 Jun; 13(8):1067-70. PubMed ID: 12060810
[TBL] [Abstract][Full Text] [Related]
74. A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis.
Morrison BM; Lachey JL; Warsing LC; Ting BL; Pullen AE; Underwood KW; Kumar R; Sako D; Grinberg A; Wong V; Colantuoni E; Seehra JS; Wagner KR
Exp Neurol; 2009 Jun; 217(2):258-68. PubMed ID: 19285073
[TBL] [Abstract][Full Text] [Related]
75. Cervical spinal cord and motor unit pathology in a canine model of SOD1-associated amyotrophic lateral sclerosis.
Katz ML; Jensen CA; Student JT; Johnson GC; Coates JR
J Neurol Sci; 2017 Jul; 378():193-203. PubMed ID: 28566164
[TBL] [Abstract][Full Text] [Related]
76. Preserving neuromuscular synapses in ALS by stimulating MuSK with a therapeutic agonist antibody.
Cantor S; Zhang W; Delestrée N; Remédio L; Mentis GZ; Burden SJ
Elife; 2018 Feb; 7():. PubMed ID: 29460776
[TBL] [Abstract][Full Text] [Related]
77. Dendrimer-2PMPA Delays Muscle Function Loss and Denervation in a Murine Model of Amyotrophic Lateral Sclerosis.
Tallon C; Sharma A; Zhang Z; Thomas AG; Ng J; Zhu X; Donoghue A; Schulte M; Joe TR; Kambhampati SP; Sharma R; Liaw K; Kannan S; Kannan RM; Slusher BS
Neurotherapeutics; 2022 Jan; 19(1):274-288. PubMed ID: 34984651
[TBL] [Abstract][Full Text] [Related]
78. Muscle specific kinase (MuSK) activation preserves neuromuscular junctions in the diaphragm but is not sufficient to provide a functional benefit in the SOD1
Sengupta-Ghosh A; Dominguez SL; Xie L; Barck KH; Jiang Z; Earr T; Imperio J; Phu L; Budayeva HG; Kirkpatrick DS; Cai H; Eastham-Anderson J; Ngu H; Foreman O; Hedehus M; Reichelt M; Hotzel I; Shang Y; Carano RAD; Ayalon G; Easton A
Neurobiol Dis; 2019 Apr; 124():340-352. PubMed ID: 30528255
[TBL] [Abstract][Full Text] [Related]
79. Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model.
Rossaert E; Pollari E; Jaspers T; Van Helleputte L; Jarpe M; Van Damme P; De Bock K; Moisse M; Van Den Bosch L
Acta Neuropathol Commun; 2019 Jul; 7(1):107. PubMed ID: 31277703
[TBL] [Abstract][Full Text] [Related]
80. NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport.
Jouroukhin Y; Ostritsky R; Assaf Y; Pelled G; Giladi E; Gozes I
Neurobiol Dis; 2013 Aug; 56():79-94. PubMed ID: 23631872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
